NBT Bank N.A. acquired a new stake in GSK PLC Sponsored ADR (NYSE:GSK – Free Report) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 19,292 shares of the pharmaceutical company’s stock, valued at approximately $929,000.
A number of other large investors also recently bought and sold shares of the stock. NewEdge Advisors LLC lifted its position in GSK by 842.9% in the second quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after buying an additional 852,437 shares during the last quarter. Foster Victor Wealth Advisors LLC increased its position in shares of GSK by 5.8% during the third quarter. Foster Victor Wealth Advisors LLC now owns 438,220 shares of the pharmaceutical company’s stock valued at $21,674,000 after acquiring an additional 23,934 shares during the last quarter. Sound Income Strategies LLC increased its position in shares of GSK by 2.7% during the third quarter. Sound Income Strategies LLC now owns 348,273 shares of the pharmaceutical company’s stock valued at $16,209,000 after acquiring an additional 9,218 shares during the last quarter. Waverly Advisors LLC raised its stake in shares of GSK by 1,372.8% in the 2nd quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock valued at $15,233,000 after acquiring an additional 270,863 shares during the period. Finally, Tidal Investments LLC raised its stake in shares of GSK by 4.6% in the 2nd quarter. Tidal Investments LLC now owns 220,236 shares of the pharmaceutical company’s stock valued at $11,545,000 after acquiring an additional 9,603 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.
GSK Stock Performance
NYSE GSK opened at $50.74 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. The company has a market cap of $102.64 billion, a P/E ratio of 15.87, a P/E/G ratio of 2.30 and a beta of 0.33. The stock has a 50-day moving average of $49.59 and a two-hundred day moving average of $51.45. GSK PLC Sponsored ADR has a 1-year low of $42.85 and a 1-year high of $61.69.
GSK (NYSE:GSK – Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. During the same quarter in the prior year, the company earned $0.47 earnings per share. The business’s quarterly revenue was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, analysts anticipate that GSK PLC Sponsored ADR will post 4.78 EPS for the current year.
GSK Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were issued a dividend of $0.4515 per share. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date was Friday, August 14th. This represents a $1.81 dividend on an annualized basis and a yield of 3.6%. GSK’s dividend payout ratio (DPR) is currently 55.31%.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on GSK shares. JPMorgan Chase & Co. restated a “sell” rating on shares of GSK in a report on Thursday, October 1st. Berenberg Bank reiterated a “buy” rating on shares of GSK in a report on Tuesday, October 6th. Sanford C. Bernstein reissued a “buy” rating on shares of GSK in a research report on Sunday, August 2nd. Royal Bank Of Canada started coverage on GSK in a research report on Tuesday, September 8th. They issued a “sector perform” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft restated a “neutral” rating on shares of GSK in a research note on Tuesday, September 29th. Four analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, GSK currently has a consensus rating of “Hold” and a consensus target price of $55.33.
Check Out Our Latest Stock Report on GSK
About GSK
GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.
Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.
Featured Stories
- Five stocks we like better than GSK
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
- Chefs’ Warehouse Has Rallied 76%—Can the Stock Keep Climbing?
- MarketBeat Week in Review – 10/19 – 10/23
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK – Free Report).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
